Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Back to Search
Print
Bookmark Trial

NCT00263874

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
La Plata, Buenos Aires, C1904AGP, Argentina
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Obstructive Pulmonary Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Moderate-severe COPD (Global inititiative for chronic Obstructive Lung Disease, GOLD, 2003 definition)

- Smoking history of at least 10 pack-years

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any significant co-morbid disease


- Use of any maintenance therapy except short acting bronchodilators

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Chronic Obstructive Pulmonary DiseaseMultiple Dose Healthy Volunteer Safety Pharmacokinetics Study
NCT00864786
  1. Bruxelles,
Male
18 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseA Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
NCT00559910
  1. La Plata, Buenos Aires
  2. Buenos Aires, Capital Federal
  3. Buenos Aires, Capital Federal
  4. Ciudad Autonoma de Buenos Aires (CABA), Capital Federal
  5. Rosario, Santa Fe
  6. Camperdown, New South Wales
  7. Daw Park, South Australia
  8. Nedlands, Western Australia
  9. Vancouver, British Columbia
  10. Winnipeg, Manitoba
  11. Hamilton, Ontario
  12. Kingston, Ontario
  13. Sainte-Foy, Quebec
  14. Providencia, Santiago, RM
  15. Valparaiso, V Región
  16. Talca,
  17. Cvikov,
  18. Kutna Hora,
  19. Liberec,
  20. Praha 5,
  21. Strakonice,
  22. Tabor,
  23. Lille,
  24. Marseille,
  25. Montpellier,
  26. Perpignan,
  27. Athens,
  28. Heraklion,
  29. Larissa,
  30. Budapest,
  31. Budapest,
  32. Deszk,
  33. Pecs,
  34. Szombathely,
  35. Anyang,
  36. Seoul,
  37. Seoul,
  38. Almere,
  39. Zutphen,
  40. Yaroslavl,
  41. Yaroslavl,
  42. Durban, Kwa-Zulu Natal
  43. Bloemfontein,
  44. Durban,
  45. Edinburgh,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseA Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers
NCT01364519
  1. Manchester, Greater Manchester
  2. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseasePhase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
NCT00263874
  1. La Plata, Buenos Aires
  2. Vicente Lopez, Buenos Aires
  3. Rosario, Santa Fé
  4. Buenos Aires,
  5. Buenos Aires,
  6. Camperdown, New South Wales
  7. Clayton, Victoria
  8. Nedlands, Western Australia
  9. Calgary, Alberta
  10. Red Deer, Alberta
  11. Hamilton, Ontario
  12. Kingston, Ontario
  13. Santiago, RM
  14. Providencia, Santiago
  15. Valparaíso,
  16. Zagreb,
  17. Olomouc,
  18. Ostrava-Poruba,
  19. Praha 5,
  20. Tabor,
  21. Debrecen,
  22. Torokbalint,
  23. Veszprem,
  24. Singapore,
  25. Singapore,
  26. Madrid,
  27. Madrid,
  28. Manchester,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
Official Title  ICMJE A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of UK-500,001 Dry Powder For Inhalation (DPI) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Pulmonary Disease, Chronic Obstructive
Intervention  ICMJE Drug: UK-500,001
Study Arms  ICMJE Not Provided
Publications * Vestbo J, Tan L, Atkinson G, Ward J; UK-500,001 Global Study Team. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J. 2009 May;33(5):1039-44. doi: 10.1183/09031936.00068908. Epub 2009 Feb 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: June 23, 2006)		324
Original Enrollment  ICMJE
 (submitted: December 8, 2005)		200
Study Completion Date  ICMJE September 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Moderate-severe COPD (Global inititiative for chronic Obstructive Lung Disease, GOLD, 2003 definition)
  • Smoking history of at least 10 pack-years

Exclusion Criteria:

  • Any significant co-morbid disease
  • Use of any maintenance therapy except short acting bronchodilators
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Canada,   Chile,   Croatia,   Czech Republic,   Hungary,   Singapore,   Spain,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00263874
Other Study ID Numbers  ICMJE A5641009
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP